Galectin-3 ablation enhances liver steatosis, but attenuates inflammation and IL-33-dependent fibrosis in obesogenic mouse model of nonalcoholic steatohepatitis

Molecular Medicine

Volumn 21, Issue , 2015, Pages 453-465

  Jeftic, Ilija ^a   Jovicic, Nemanja ^a   Pantic, Jelena ^a   Arsenijevic, Nebojsa ^a   Lukic, Miodrag L ^a   Pejnovic, Nada ^a  

^a UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; CD11B ANTIGEN; CD14 ANTIGEN; CD36 ANTIGEN; CRYOPYRIN; FAS ANTIGEN; GALECTIN 3; GLYCOPROTEIN P 15095; INFLAMMASOME; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 33 RECEPTOR; INTERLEUKIN RECEPTOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; IL33 PROTEIN, MOUSE; LGALS3 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ABDOMINAL OBESITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CONTROLLED STUDY; DIABETES MELLITUS; GENE EXPRESSION; GENOTYPE; HEPATITIS; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPID DIET; LIVER CELL DAMAGE; LIVER FIBROSIS; MACROPHAGE; MALE; MONOCYTE; MOUSE; MYELOID DENDRITIC CELL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WILD TYPE MOUSE; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; FATTY LIVER; FIBROSIS; GENETICS; HUMAN; LIVER; METABOLISM; PATHOLOGY;

ANIMALS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY LIVER; FIBROSIS; GALECTIN 3; HUMANS; INFLAMMATION; INTERLEUKIN-33; LIVER; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940781164     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2014.00178     Document Type: Article

References (49)

1. Lumeng CN, Saltiel AR. (2011) Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 121:2011–7
2. Chalasani N, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 55:2005–23
3. Day CP, James OF. (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology. 114:842–5
4. Friedman, S.L. (2010) Evolving challenges in hepatic fibrosis. Nat. Rev. Gastroenterol. Hepatol. 7:425–36
5. Dumic J, et al. (2006) Galectin-3: an open-ended story. Biochim. Biophys. Acta. 1760:616–35
6. Liu FT. (2005) Regulatory roles of galectins in the immune response. Int. Arch. Allergy. Immunol. 136:385–400
7. Henderson NC, et al. (2009) The regulation of inflammation by galectin-3. Immunol. Rev. 230:160–71
8. Radosavljevic G, et al. (2010) The roles of Galectin-3 in autoimmunity and tumor progression. Immunol. Res. 52:100–10
9. Li Y, et al. (2008) Galectin-3 is a negative regulator of lipopolysaccharide-mediated inflammation. J. Immunol. 181:2781–9
10. Pang J, et al. (2013) Increased adiposity, dysregulated glucose metabolism and systemic inflammation in galectin-3 KO mice. PLoS One. 8:e57915
11. Pejnovic NN, et al. (2013) Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets. Diabetes. 62:1932–44
12. Iacobini C, et al. (2009) Accelerated lipid-induced atherogenesis in galectin-3 deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscler. Thromb. Vasc. Biol. 29:831–6
13. Nomoto K, et al. (2006) Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. J. Pathol. 210:469–77
14. Nomoto K, et al. (2008) Nonalcoholic steatohepatitis and hepatocellular carcinoma in galectin-3 knockout mice. Hepatol. Res. 38:1241–51
15. Iacobini C, et al. (2011) Galectin-3 ablation protects mice from diet-induced NASH: A major scavenging role for galectin-3 in liver. J. Hepatol. 54:975–83
16. Hsu DK, et al. (1999) Galectin 3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int. J. Cancer. 81:519–26
17. Baeck C, et al. (2012) Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut. 61:416–26
18. Miura K, Yang L, van Rooijen N, Ohnishi H, Seki E. (2012) Hepatic recruitment of macro - phages promotes nonalcoholic steatohepatitis through CCR2. Am. J. Physiol. Gastrointest. Liver. Physiol. 302:1310–21
19. Tacke F, Zimmermann HW. (2014) Macrophage heterogeneity in liver injury and fibrosis. J. Hepatol. 60:1090–6
20. Martinez FO, Sica A, Mantovani A, Locati M. (2008) Macrophage activation and polarization. Front. Biosci. 13:453–61
21. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. (2014) Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat. Rev. Immunol. 14:181–94
22. Henderson NC, et al. (2006) Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc. Natl. Acad. Sci. U.S.A. 103:5060–5
23. Li LC, Li J, Gao J. (2014) Functions of galectin-3 and its role in fibrotic diseases. J. Pharmacol. Exp. Ther. 351:336–43
24. Yang Z, et al. (2013) Macrophages as IL-25/IL-33- responsive cells play an important role in the induction of type 2 immunity. PLoS One. 8:e59441
25. Mchedidze T, et al. (2013) Interleukin-33- dependent innate lymphoid cells mediate hepatic fibrosis. Immunity. 39:357–71
26. Palmer G. and Gabay C. (2011) Interleukin-33 biology with potential insights into human diseases. Nat. Rev. Rheumatol. 7:321–9
27. Liu Y, et al. (2011) IL-13 induces connective tissue growth factor in rat hepatic stellate cells via TGF- -independent Smad signaling. J. Immunol. 187:2814–23
28. Matthews DR, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:412–9
29. Kleiner DE, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41:1313–21
30. Harley IT, et al. (2014) IL-17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology. 59:1830–9
31. Deutch MJ, Schriever SC, Roscher AA, Ensenauer R. (2014) Digital image analysis approach for lipid droplet size quantitation of Oil Red Ostained cultured cells. Anal. Biochem. 445:87–9
32. Hadi AM, et al. (2010) Rapid quantification of myocardial fibrosis: A new macro-based automated analysis. Anal. Cell. Pathol. (Amst). 33:257–69
33. Volarevic V, et al. (2012) Protective role of IL- 33/ST2 axis in Con A-induced hepatitis. J. Hepatol. 56:26–33
34. Trotier MD, Naaz A, Li Y, Fraker PJ. (2012) Enhancement of hematopoiesis and lymphopoiesis in diet-induced obese mice. Proc. Natl. Acad. Sci. U.S.A. 109:7622–9
35. Livak KJ and Schmittgen TD. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–8
36. Stanton MC, et al. (2011) Inflammatory signals shift from adipose to liver during high fat feeding and influence the development of steatohepatitis in mice. J. Inflamm. (Lond.). 8:8
37. Nguyen MT, et al. (2007) A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Tolllike receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 282:35279–92
38. Ganz M, Szabo G. (2013) Immune and inflammatory pathways in NASH. Hepatol. Int. 7:771–81
39. Jie Zhou, et al. (2008) hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPAR-gin promoting steatosis. Gastroenterology. 134:556–67
40. Patsouris D, et al. (2008) Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell. Metabolism. 8:301–9
41. Stefanovic-Racic M, et al. (2012) Dendritic cells promote macrophage infiltration and comprise a substantial proportion of obesity-associated increases in CD11c+ cells in adipose tissue and liver. Diabetes. 61:2330–9
42. Obstfeld AE, et al. (2010) C-c chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes. 59:916–25
43. Csak T, et al. (2011) Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology. 54:133–44
44. Miura K, et al. (2010) Toll-like receptor 9 promotes steatohepatitis by induction of interleukin- 1beta in mice. Gastroenterology. 139:323–34
45. Dixon LJ, Berk M, Thapaliya S, Papouchado BG, Feldstein AE. (2012) Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab. Invest. 92:713–23
46. Bléroit C, et al. (2015) Liver-resident macrophage necroptosis orchestrates type 1 microbicidal inflammation and type-2-mediated tissue repair during bacterial infection. Immunity. 42:145–58
47. Shan M, et al. (2013) Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science. 342:447–53
48. Li D, et al. (2014) IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J. Allergy. Clin. Immunol. 134:1422-32.e11
49. Milovanovic M, et al. (2012) IL-33/ST2 axis in inflammation and immunopathology. Immunol. Res. 52:89–99.